The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and life-threatening disease with symptoms of hemolysis and thrombosis. Current therapies for this complement-mediated disease rely predominantly on inhibition of the C5 complement protein. However, data on treatment responses and quality of life i...

Descripción completa

Detalles Bibliográficos
Autores principales: Dingli, David, Matos, Joana E., Lehrhaupt, Kerri, Krishnan, Sangeeta, Yeh, Michael, Fishman, Jesse, Sarda, Sujata P., Baver, Scott B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720163/
https://www.ncbi.nlm.nih.gov/pubmed/34973099
http://dx.doi.org/10.1007/s00277-021-04715-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720163/
https://www.ncbi.nlm.nih.gov/pubmed/34973099
http://dx.doi.org/10.1007/s00277-021-04715-5

Ejemplares similares